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Evaluation of Diffusing Capacity in
Patients With a Restrictive Lung
Disease*
Henk Stam, PhD; Ted A. W. Splinter, PhD, MD; and Adrian Versprille, PhD
Background: In healthy volunteers, the single-breath diffusing capacity of the lung for carbon
monoxide (DLCO) decreases and DLCO normalized per liter alveolar volume (VA; DLCO/VA)
increases if VA is decreased. We hypothesized that comparison of DLCO/VA with its predicted value
at predicted total lung capacity (TLC) will result in an underestimation of the diffusion disorder
in patients with a restrictive lung disease, if a similar relationship exists between DLCO/VA and
lung volume as found in healthy volunteers.
Objective: To test this hypothesis, we studied total gas transfer DLCO and DLCO/VA as functions of
VA in patients who developed a restrictive lung disease and a diffusion disorder in a short period
of time.
Design: An observational survey.
Setting: Pulmonary function department.
Patients: Thirteen patients without any initial pulmonary pathology who developed the men-
tioned pulmonary pathology due to bleomycin treatment.
Interventions: Bleomycin treatment.
Measurements and results: We performed the single-breath test at various VA levels before,
during, and after bleomycin treatment. In the majority of the patients, the DLCO vs VA
relationship remained parabolic, but shifted downwards during therapy. Therefore, the linear
DLCO/VA vs VA relationship shifted downwards, while the negative slope was not changed,
indicating the development of a decreased gas transfer. Six patients also developed a volume
restriction.
Conclusions: The agreement of the data with the hypothesis increased its probability. Conse-
quently, to evaluate a diffusion disorder, DLCO/VA at a lower actual TLC of patients with a lung
restriction should be compared to a reference DLCO/VA at a lung volume equal to the actual TLC.
(CHEST 2000; 117:752–757)
Key words: alveolar volume; bleomycin; chemotherapy; diffusing capacity; restrictive lung disease
Abbreviations: Dlco 5 diffusing capacity of the lung for carbon monoxide; Dlco/Va 5 diffusing capacity of the lung
for carbon monoxide normalized per liter alveolar volume; Hb 5 hemoglobin concentration; TLC 5 total lung capacity;
TLCsb 5 total lung capacity determined with the single-breath test; TLCmb 5 total lung capacity determined with the
multiple-breath He washin method; Va 5 alveolar volume; VC 5 vital capacity
In healthy volunteers, the diffusing capacity of thelung for carbon monoxide (Dlco) decreases and the
Dlco per liter alveolar volume (Va; Dlco/Va) in-
creases if Va is decreased.1–12 Dlco/Va vs Va yields a
linear relationship with a negative slope.1,2,11,12 In
patients with a volume restriction due to intra- or
extraparenchymal diseases, Dlco and Dlco/Va are
determined at a total lung capacity (TLC) below their
predicted TLC.13 Based on our previous analyses in
healthy volunteers, we advised comparing Dlco/Va in
patients with a restrictive lung disease with a reference
value counting for a lung volume equal to the patients’
TLC.2,3 However, such advice only holds good if the
relationship between Dlco/Va and Va is similar to that
in normal subjects. Therefore, we hypothesized that in
patients with a restrictive lung disease, Dlco/Va is
decreased by the diffusion disorder and increased by
the volume decrease. As a consequence, Dlco/Va
should be compared with predicted values of Dlco/Va
at a lung volume equal to the disease-limited TLC to
evaluate the diffusion disorder at alveolar to capillary
membrane.
*From the Pathophysiology Laboratory of the Department of
Pulmonary Diseases (Drs. Stam and Versprille), Erasmus Uni-
versity; and the Department of Medical Oncology (Dr. Splinter),
University Hospital Dijkzigt, Rotterdam, The Netherlands.
Manuscript received April 12, 1999; revision accepted September
17, 1999.
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To test this hypothesis, we studied the volume
dependence of the diffusion indexes in a group of
patients who gradually developed a diffusion disor-
der, whether or not in combination with a volume
restriction, in a relatively short period. Such pro-
cesses may occur in patients receiving bleomycin in
a chemotherapeutic regimen. An important side
effect of bleomycin is lung damage, characterized by
pneumonitis or diffuse interstitial pulmonary fibro-
sis,14,15 with a decrease in TLC, diffusion indexes, or
both.16 Dlco appeared to be the best indicator of
early lung damage.17 This index enables an early
discontinuation of bleomycin treatment at a stage
when lung toxicity is still reversible.18 In a group of
patients receiving bleomycin, we estimated Dlco
and Dlco/Va at different lung volumes before,
during, and after treatment.
Materials and Methods
The protocol was approved by the Erasmus University review
board for human studies.
Subjects
In 13 adult men suffering from germ cell tumors but without
any initial pulmonary pathology, Dlco and Dlco/Va were
determined. The spirometric data before the chemotherapeutic
treatment, expressed as a mean percentage of predicted values
6 SD of the European Community for Coal and Steel,13 were as
follows: TLC, 101 6 8%; vital capacity (VC), 99 6 12%; and
FEV1 as a fraction of VC, 98 6 10%. Mean Dlco and Dlco/Va
at TLC, corrected to a normal hemoglobin (Hb) concentration,
were 87 6 14% and 94 6 15% of the predicted value, respec-
tively.1 Their ages ranged from 20 to 35 years. Predicted values of
Hb concentration were 148 6 8 g/L and 132 6 8 g/L in men and
women, respectively, as determined in a group of 120 volunteers
with the same demographic background in the Laboratory for
Clinical Chemistry in our hospital (J. Lindemans, PhD; unpub-
lished data; July 1992).
Procedures and Protocol
In a series of 12 single-breath maneuvers, in which the subjects
expired to residual volume and then held their breath after
inspiring volumes ranging from 1.5 L up to VC in a random
order, Dlco and Dlco/Va were determined in a sitting position
at various Va levels.1 The single-breath procedures were per-
formed with a Masterlab Transfer (Jaeger; Wu¨rzburg, Germany)
following the European Community for Coal and Steel guide-
lines.13 The start of effective breath-holding time was taken when
30% of the inspiration time had elapsed, and the end when half
of the expired sample had been collected. Overall breath-holding
time slightly exceeded 10 s. Inspirations and expirations were
performed rapidly.
Alveolar fractions of CO and He were obtained from expired
gas after discarding 800 mL for washout of airways and apparatus
dead space. The size of the alveolar sample was 800 mL. At least
5 min elapsed between consecutive measurements. To minimize
the influence of CO back tension, the number of measurements
was restricted to six a day. Before each series of measurements,
patients rebreathed for several minutes in an air-filled bellows
system, in which CO2 was absorbed and O2 was supplemented.
The CO concentration was read from the analyzer, when its level
in the rebreathing system was constant. Because this CO con-
centration in the rebreathing system appeared to be , 1% of the
alveolar CO tension at the start of breath holding, back tension
was neglected. If a sigh occurred, we waited 5 min before
performing the next measurement.1,5,12,19 The Masterlab Trans-
fer used a heat conductivity type He analyzer that is sensitive to
CO2. Therefore, CO2 was absorbed prior to both He and CO
analysis. The expiratory gas concentrations were corrected for an
absorbed volume corresponding to 5% CO2.20
Effects of variation in Hb concentration during the period of
chemotherapy were eliminated by correction to the patients’ Hb
concentration before treatment. For this correction, we used the
following equation:
Dlco/Va (corr) 5 Dlco/Va (obs).(a 1 us[Hb])/([a 1 us].[Hb])
Where Dlco/Va(corr) is Dlco/Va corrected to pretreatment
Hb concentration; Dlco/Va (obs) is the observed Dlco/Va at
the actual Hb concentration during chemotherapy; a is the ratio
of membrane conductance and capillary blood volume (in tradi-
tional units [milliliters, minute, and millimeters Hg], approxi-
mately 0.7); and us is the reaction rate for the CO Hb reaction at
an O2 pressure of 110 mm Hg and normal Hb concentration (in
traditional units, 1.0).13,21
Spirometry, performed with a water-sealed spirometer, and the
Dlco/Va vs Va relationships were determined before treatment
and immediately after two and four chemotherapeutic treat-
ments. The measurements were repeated at 6 months and at 1
year after the last treatment. Ventilation distribution was evalu-
ated on the basis of the ratio between TLC determined with the
single-breath test (TLCsb) and TLC determined with the multi-
ple-breath He washin method (TLCmb). A TLCsb/TLCmb ratio
. 0.85 has been proposed as an indication for normal ventilation
distribution.22
The patients received combination chemotherapy, consisting
of cisplatin, 20 mg/m2 body surface area, on days 1 to 5;
etoposide, 100 mg/m2 body surface area, on days 1 to 5; and 30
mg bleomycin IV push on days 2, 9, and 16. Courses were
repeated every 3 weeks. The maximum total dose of bleomycin
was 360 mg.
Statistics
Changes were tested with use of a paired Student’s t test.
Differences between two groups of data were regarded as
significant at p value , 0.05.
Results
In all patients, the Hb concentration decreased
significantly during therapy (Tables 1, 2; p value
, 0.001, paired t test). After two and four bleomycin
treatments, the average decreases in Hb concentra-
tion 6 SD were 17 6 8% and 27 6 8%, respectively.
We separated the patients in two groups: in one
group, the TLC decreased by . 10% of the pretreat-
ment TLC (Table 1); in the other group, the TLC
changed , 10% from baseline TLC (Table 2). Ven-
tilation distribution was evaluated on the basis of the
TLCsb/TLCmb ratio. This ratio was . 0.85 in all
patients at all stages of therapy.
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DLCO/VA vs VA Relationships
A typical example of the relationships between
the diffusion indexes and Va before and after four
treatments with bleomycin (solid lines) and during
recovery (dotted lines) is given in Figure 1 for a
patient in which Dlco/Va, Dlco, and TLC were
decreased due to chemotherapy. The dashed lines
with shaded areas in Figure 1 represent the
volume-dependent predicted values 6 1 SD.1 The
Dlco/Va vs Va relationship before treatment was
within 1 SD from the predicting equation. The
Dlco/Va vs Va relationship after four treatments
decreased . 4 SD in parallel to the predicted and
pretreatment Dlco/Va vs Va relationships. After
6 months, the Dlco/Va vs Va relationship re-
turned toward the initial position, but remained
about 2 SD below predicted and did not improve
further in the next 6 months. If we regard the
initial value of Dlco/Va at the initial TLC as
100% (A), then Dlco/Va at the treatment limited
TLC after four treatments with bleomycin (B)
decreased 25% (B with respect to A). When
Dlco/Va after four treatments was compared with
pretreatment Dlco/Va at a volume similar to the
treatment-limited TLC (C), a larger decrease of
36% (B with respect to C) was found.
In all patients, Dlco/Va vs Va was linear before,
during, and after treatment (Tables 1, 2). The slope
(b) of the Dlco/Va vs Va relationships did not
change after four chemotherapeutic treatments
(p 5 0.30). The relationships of Dlco/Va vs Va
shifted downwards, implying that Dlco/Va at all
lung volumes, including TLC, was significantly de-
creased with respect to its pretreatment values (p
value , 0.001 for both groups).
In Tables 1, 2, we compared Dlco/Va at actual
TLC during and after chemotherapy, both with
the pretreatment Dlco/Va at pretreatment TLC,
and at a similar lung volume equal to the TLC
after four treatments with bleomycin. In patients
who developed a volume restriction (Table 1),
Dlco/Va at actual TLC decreased more when
compared to pretreatment Dlco/Va at the same
lung volume (23 6 9%) than when compared to
Table 1—Change in Hb Concentration, TLC, and DLCO/VA vs VA Relationship Dependent on the Stage of the




Recovery Hb, g/L TLC, L
Dlco/Va 5 a 2 b Va







1 Pre 154 8.00 0.70 10.78 20.98 5.17 (100) 6.09 (100)
2t 140 7.77 0.79 10.80 20.96 4.64 (90) 5.48 (90)
4t 129 6.71 0.77 9.64 20.98 4.48 (87) 4.48 (74)
1y 150 7.35 0.76 10.07 20.98 4.48 (87) 4.96 (81)
2 Pre 158 7.56 0.41 7.20 20.99 4.08 (100) 4.40 (100)
2t 132 7.91 0.49 7.40 20.99 3.49 (86) 4.06 (92)
4t 90 6.78 0.41 6.20 20.99 3.40 (83) 3.40 (77)
3 Pre 153 7.13 0.54 9.15 20.97 5.30 (100) 6.07 (100)
2t 127 7.21 0.54 8.07 20.96 4.15 (78) 4.96 (82)
4t 100 5.72 0.55 7.03 20.89 3.87 (73) 3.87 (64)
1y 148 6.61 0.51 8.20 20.98 4.87 (92) 5.32 (88)
4 Pre 150 9.43 0.22 5.55 20.93 3.45 (100) 3.76 (100)
2t 122 9.39 0.25 5.66 20.95 3.33 (96) 3.63 (97)
4t 105 8.11 0.32 5.83 20.92 3.17 (92) 3.17 (84)
1y 138 8.61 0.26 5.71 20.84 3.44 (100) 3.58 (95)
5 Pre 156 7.42 0.54 7.79 20.92 3.78 (100) 4.40 (100)
2t 103 7.15 0.52 7.40 20.95 3.65 (97) 4.12 (93)
4t 109 6.26 0.43 6.63 20.80 3.96 (105) 3.96 (90)
1y 138 7.29 0.46 6.56 20.93 3.22 (85) 3.69 (84)
6 Pre 122 5.67 0.66 7.75 20.95 4.03 (100) 5.35 (100)
2t 92 5.62 0.59 6.70 20.92 3.37 (84) 4.53 (85)
4t 97 4.95 0.55 6.02 20.91 3.31 (82) 4.00 (75)
1⁄2 y 119 3.65 0.79 6.41 20.90 3.51 (87) 3.50 (65)‡
*Pt 5 patient; Pre 5 before chemotherapy; 2t 5 after two treatments with bleomycin; 4t 5 after four treatments with bleomycin; 1y 5 1 year
after last (fourth) treatment with bleomycin; a and b are linear regression coefficients, and r is the correlation coefficient;
%Pretreatment 5 percentage of pretreatment value; 1⁄2 y 5 6 months after last (fourth) treatment with bleomycin.
†Lung volume is TLC after four bleomycin courses.
‡Smallest lung volume is TLC after 6 months, and patient died before the 1-year stage.
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pretreatment Dlco/Va at pretreatment TLC (the
difference of both methods of comparison is
10 6 3%; p value , 0.001, paired t test). In
patients without a volume restriction (Table 2),
actual Dlco/Va was compared with pretreatment
Dlco/Va at pretreatment TLC. After four
courses, the decrease in Dlco/Va was on average
15 6 11% of the pretreatment value.
Discussion
Ventilation distribution was evaluated on the basis
of the ratio between TLCsb and TLCmb. In all
patients at all stages of treatment, the TLCsb/
TLCmb ratio was . 0.85, which has been proposed
as an indication for normal ventilation distribution.22
When ventilation unequality is increased (for in-
stance in elderly or COPD patients), this ratio is
decreased and gas transfer is primarily studied in the
best ventilated areas.
During bleomycin treatment, the patients devel-
oped a volume restriction or a diffusion disorder, or
both. Furthermore, the relationships between Dlco
or Dlco/Va and Va remained parabolic and linear,
respectively, the latter with a negative slope, as in
healthy volunteers. Probably because the alveolar
membrane expands in a similar way, its change in gas
transfer capacity is comparable.11,12 Both relation-
ships decreased to a lower level, partly due to a
decrease in Hb concentration. To evaluate the dif-
fusion disorder, we corrected the data to pretreat-
ment Hb concentrations.
The data are in agreement with our hypothesis
that Dlco/Va is decreased by the diffusion disor-
der and increased by the volume restriction. Ex-
trapolation of Dlco/Va to patients’ TLC before
treatment, or to reference TLC, will result in a
Dlco/Va lower than the actual Dlco/Va at actual
TLC (except when no volume restriction would
have occurred). Consequently, in those patients
who developed a volume restriction (Table 1), the
difference between Dlco/Va at actual TLC dur-
Table 2—Change in Hb Concentration, TLC, and DLCO/VA vs VA Relationship Dependent on the Stage of the




Recovery Hb, g/L TLC, L








7 Pre 164 6.96 0.37 7.48 20.97 4.89 (100) 4.98 (100)
2t 126 7.12 0.46 7.38 20.95 4.12 (84) 4.30 (86)
4t 129 6.74 0.44 7.61 20.98 4.65 (95) 4.65 (94)
1y 161 6.44 0.31 6.62 20.88 4.60 (94) 4.51 (91)
8 Pre 147 8.46 0.38 6.42 20.96 3.20 (100) 3.42 (100)
2t 137 8.23 0.37 6.07 20.93 3.01 (94) 3.13 (92)
4t 109 7.91 0.38 5.72 20.93 2.76 (86) 2.76 (81)
1y 166 7.62 0.38 6.11 20.98 3.20 (100) 3.10 (91)
9 Pre 158 6.88 0.79 10.01 20.96 4.58 (100) 4.67 (100)
2t 147 6.90 0.89 9.55 20.96 3.42 (75) 3.54 (76)
4t 95 6.76 0.86 9.39 20.91 3.60 (79) 3.60 (77)
1y 142 6.49 1.03 10.85 20.99 4.13 (90) 3.87 (83)
10 Pre 118 7.40 0.50 7.36 20.91 3.63 (100) 3.47 (100)
2t 103 8.09 0.53 7.46 20.88 3.19 (88) 3.40 (98)
4t 95 7.70 0.52 7.58 20.88 3.58 (99) 3.58 (103)
1y 138 8.10 0.55 7.87 20.93 3.37 (93) 3.60 (104)
11 Pre 158 7.89 0.77 10.20 20.96 4.15 (100) 4.26 (100)
2t 129 8.59 0.69 9.37 20.93 3.49 (84) 4.06 (95)
4t 126 7.75 0.75 9.26 20.91 3.45 (83) 3.45 (81)
1y 156 7.94 0.72 9.85 20.97 4.17 (101) 4.31 (101)
12 Pre 130 6.30 0.54 6.90 20.91 3.47 (100) 3.26 (100)
2t 105 6.62 0.50 6.09 20.92 2.79 (80) 2.77 (85)
4t 89 6.67 0.43 5.81 20.91 2.92 (84) 2.92 (90)
1y 137 6.79 0.36 5.94 20.86 3.51 (101) 3.54 (109)
13 Pre 147 7.73 0.26 6.54 20.91 4.51 (100) 4.53 (100)
2t 134 7.55 0.21 5.56 20.77 3.97 (88) 3.94 (87)
4t 113 7.66 0.47 6.83 20.94 3.19 (71) 3.19 (70)
1y 140 7.27 0.51 7.55 20.94 3.79 (84) 3.60 (80)
*See Table 1 for abbreviations.
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ing chemotherapy (B in Fig 1, bottom, b) and the
pretreatment Dlco/Va at pretreatment TLC (A in
Fig 1, bottom, b) is significantly smaller than the
difference in Dlco/Va with respect to pretreat-
ment Dlco/Va (C in Fig 1, bottom, b) at similar
lung volume. We concluded that comparison of
Dlco/Va at a treatment-limited TLC with the
Dlco/Va at the initial or predicted TLC implies
an underestimation of the diffusion disorder.
Since our results (Fig 1, bottom, b, C and C’)
revealed that the pretreatment values of our pa-
tients were similar to their predicted values, sim-
ilar studies on other restrictive diseases can be
done by comparison of the actual Dlco/Va vs Va
relationship with the predicted relationship.1
This study supports the hypothesis that the effect
of a volume restriction caused by bleomycin treat-
ment on the diffusion indexes is comparable to that
of a voluntary volume reduction in healthy volun-
teers. Although our results only apply for patients
with a restrictive disease due to bleomycin treat-
ment, we would recommend, at this stage of knowl-
edge, comparing actual Dlco/Va with its predicted
value at the same lung volume as the disease-limited
TLC in patients with other restrictive lung diseases.1
However, to evaluate the individual decrease in total
diffusing capacity, we recommend comparing the
Hb-corrected Dlco in patients with a restrictive
lung disease with a predicted Dlco at predicted
TLC. Dlco in percentage of its predicted value at
predicted TLC reflects the total effect of both
volume restriction and alveolar capillary diffusion
disorder on Dlco.
In this study, we performed 12 measurements
on each patient before, during, and after the
treatment with bleomycin, to illustrate that the
slopes of the linear Dlco/Va vs Va relationships
are not changed. In practice, however, to monitor
the side effect of bleomycin on lung tissue, using
the estimation of Dlco and Dlco/Va at a large
number of Va levels before, during, and after the
courses of chemotherapy is time consuming.
Therefore, we recommend determining the rela-
tionship between Dlco/Va and Va before chemo-
therapy and to estimate Dlco/Va during the
courses of medication at the actual TLC only, or to
compare Dlco/Va during chemotherapy with pre-
dicted values, taking a volume restriction into
account.1 During chemotherapy, Dlco/Va is mea-
sured at the treatment-limited TLC only and is
compared with the pretreatment or predicted
Dlco/Va at the same volume. To determine the
relationship between Dlco/Va and Va in this
study, we performed a relatively large number of
measurements; in practice, about six measure-
ments at various Va levels appear to be sufficient
for proper regression analysis.
In this study, all patients were relatively young,
and in normal subjects, as described in our former
article,1 the slope of the Dlco/Va vs Va relationship
is steepest at younger ages. We assume that a
comparable age dependency holds in patients with a
restrictive lung disease. Therefore, we would postu-
late that the influence of volume changes on
Dlco/Va is less important in elderly patients with a
restrictive lung disease.
ACKNOWLEDGMENT: The authors thank W. J. Paterson for
grammatical corrections.
Figure 1. Individual example (subject 3; Table 1) of Dlco vs Va
(top, a) and Dlco/Va vs Va relationships (bottom, b), respec-
tively, before and after four courses of chemotherapy containing
bleomycin (solid lines) and after 1 year of recovery (dashed lines)
in a patient who developed a diffusion disorder as well as a
volume restriction. The dashed lines in the shaded areas repre-
sent the volume-dependent predicted values 6 1 SD, as found in
a previous study.1 F 5 before chemotherapy; f 5 after four
courses with bleomycin-containing chemotherapy; E 5 1 year
after the last treatment; A 5 Dlco/Va and Dlco values at initial
TLC; B 5 Dlco/Va and Dlco values at the disease-limited
TLC after four courses with bleomycin-containing chemother-
apy; C 5 Dlco/Va and Dlco values before chemotherapy at a
Va equal to the TLC after chemotherapy; C’ 5 Dlco/Va and
Dlco predicted values at a Va equal to the TLC after chemo-
therapy.
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